. 2021 Oct 18;10(11):1455–1462. doi: 10.1530/EC-21-0362
This work is licensed under a Table 2.
Comparison (baseline and in-hospital stay) of previous euthyroid and previous hypothyroid groups.
| Characteristics | Previously euthyroid (n = 193) | Previously hypothyroid (n = 43) | P value |
|---|---|---|---|
| Age (years; n = 236) | 53 (15–89) | 63 (31–91) | 0.002 |
| Female sex | 58 (40.6%) | 19 (44.2%) | 0.074 |
| BMI (kg/m2; n = 75) | 27.7 (15.7–46.4) | 27.8 (23.5–35.6) | 0.601 |
| SBP (mmHg; n = 236) | 130 (99–178) | 130 (105–180) | 0.157 |
| DBP (mmHg; n = 236) | 80 (50–100) | 80 (60–100) | 0.795 |
| Comorbidities (n = 236) | 121 (62.7%) | 34 (79.1%) | 0.041 |
| Diabetes (n = 236) | 96 (49.7%) | 23 (46.5%) | 0.657 |
| Hypertension (n = 236) | 74 (38.3%) | 28 (65.1%) | 0.001 |
| CAD (n = 236) | 14 (7.3%) | 5 (11.6%) | 0.354 |
| Respiratory (n = 236) | 12 (6.2%) | 3 (6.9%) | 0.854 |
| CKD (n = 236) | 2 (1%) | 4 (9.3%) | 0.002 |
| Cancer (n = 236) | 7 (3.6%) | 1 (2.3%) | 0.67 |
| Others (n = 236) | 36 (18.7%) | 13 (30.2%) | 0.09 |
| Symptomatic cases (n = 236) | 183 (94.8%) | 40 (93%) | 0.641 |
| Duration of symptoms (days; n = 215) | 5 (1–20) | 5 (1–15) | 0.967 |
| Baseline SpO2 (%; n = 229) | 97 (66–100) | 96 (75–99) | 0.006 |
| Baseline OSCI (n = 236) | |||
| 3.0 | 151 | 30 | |
| 4.0 | 31 | 10 | 0.614 |
| 5.0 | 10 | 3 | |
| 7.0 | 1 | 0 | |
| Hospital stay (n = 236) | 8 (2–44) | 10 (1–25) | 0.084 |
| Outcome OSCI (n = 236) | |||
| 3.0 | 127 | 23 | |
| 4.0 | 47 | 10 | |
| 5.0 | 15 | 7 | 0.445 |
| 6.0 | 1 | 0 | |
| 7.0 | 1 | 1 | |
| 8.0 | 9 | 2 | |
| Change in severity (n = 236) | 48 (24.9%) | 13 (30.2%) | 0.708 |
| Severe cases (n = 236) | 26 (13.5%) | 10 (23.3%) | 0.107 |
| Oxygen (n = 236) | 73 (37.8%) | 20 (46.5%) | 0.292 |
| Oxygen flow (n = 236) | |||
| Low flow | 47 (24.4%) | 10 (23.3%) | 0.456 |
| High flow | 26 (13.5%) | 9 (20.9%) | |
| ICU admission (n = 236) | 28 (14.5%) | 12 (27.9%) | 0.034 |
| ICU days (n = 40) | 9.5 (1–34) | 8.5 (3–19) | 0.590 |
| RRT (n = 236) | 3 (1.6%) | 1 (2.3%) | 0.723 |
| Inotropic support (n = 236) | 10 (5.2%) | 3 (6.9%) | 0.641 |
| Mortality (n = 236) | 9 (4.7%) | 2 (4.7%) | 0.997 |
| CRP (mg/L; n = 228) | 6.4 (0.1–288.9) | 9 (0.4–254.8) | 0.353 |
| IL-6 (pg/mL; n = 198) | 12.9 (0–1109) | 19.7 (0–1158) | 0.061 |
| LDH (U/L; n = 224) | 259 (146–826) | 255 (129–466) | 0.884 |
| D-dimer (ng/mL; n = 233) | 144.5 (0–15,057) | 176 (0–3888) | 0.15 |
| Ferritin (ng/mL, n = 226) | 143.5 (3–5317) | 206.1 (16.3–7158.4) | 0.032 |
| Free T4 (ng/dL; n = 235) | 0.97 (0.58–1.70) | 1.12 (0.57–1.56) | 0.017 |
| Free T3 (pg/mL; n = 236) | 2.92 (1.61–4.24) | 2.67 (1.64–4.27) | 0.006 |
| TSH (mIU/mL; n = 235) | 1.83 (0.04–35.49) | 2.43 (0.15–39.15) | 0.143 |
CAD, coronary artery disease; CKD, chronic kidney disease; CRP, C-reactive protein; DBP, diastolic blood pressure; ICU, intensive care unit; IL-6, interleukin-6; LDH, lactate dehydrogenase; OSCI, ordinal scale for clinical improvement; RRT, renal replacement therapy, SBP, systolic blood pressure; SpO2, baseline oxygen saturation; TSH, thyroid-stimulating hormone.